Published in Gut on July 01, 2005
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int (2009) 2.33
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut (2010) 1.59
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
Insulin resistance and hepatitis C. World J Gastroenterol (2006) 1.33
Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol (2012) 1.22
Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol (2008) 1.17
Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol (2006) 1.09
The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut (2007) 1.06
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci (2012) 1.01
Insulin resistance and steatosis in hepatitis C virus infection. Gut (2005) 1.00
Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. Hepatology (2010) 0.99
Molecular mechanisms of insulin resistance in chronic hepatitis C. World J Gastroenterol (2009) 0.98
Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World J Hepatol (2014) 0.96
Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis. Mol Med (2011) 0.95
Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance and oxidative stress. Viruses (2009) 0.94
Hepatic steatosis: a benign disease or a silent killer. World J Gastroenterol (2008) 0.92
Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol (2016) 0.91
Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review. Dig Dis Sci (2015) 0.91
Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. World J Gastroenterol (2012) 0.90
Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne) (2015) 0.89
The interaction between insulin resistance, liver fibrosis and early virological response in Egyptian patients with chronic hepatitis C. Can J Gastroenterol (2012) 0.88
Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol (2016) 0.88
An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol (2013) 0.87
Hepatitis C virus experimental model systems and antiviral drug research. Virol Sin (2010) 0.87
Interaction between hepatitis C virus and metabolic factors. World J Gastroenterol (2014) 0.87
Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. Can J Gastroenterol (2009) 0.86
Insulin resistance is common in patients with predominantly genotype 3 chronic hepatitis C. Dig Dis Sci (2009) 0.86
Hepatitis C Virus, Insulin Resistance, and Steatosis. J Clin Transl Hepatol (2016) 0.85
Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci (2009) 0.83
Insulin sensitivity and variability in hepatitis C virus infection using direct measurement. Dig Dis Sci (2012) 0.83
Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance. PPAR Res (2009) 0.83
Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y) (2016) 0.83
Hepatitis C virus to hepatocellular carcinoma. Infect Agent Cancer (2012) 0.82
Metabolic syndrome in patients with chronic hepatitis C virus genotype 1 infection who do not have obesity or type 2 diabetes. Clinics (Sao Paulo) (2012) 0.82
An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study. BMC Gastroenterol (2007) 0.82
Fatty liver in chronic hepatitis C infection: unravelling the mechanisms. Gut (2007) 0.81
Apelin serum level in Egyptian patients with chronic hepatitis C. Mediators Inflamm (2011) 0.81
Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis? Gut (2006) 0.81
Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance. Oncol Rep (2013) 0.80
NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci (2016) 0.80
Investigation of the factors associated with circulating soluble CD36 levels in patients with HCV-related chronic liver disease. Diabetol Metab Syndr (2013) 0.79
PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients. Sci Rep (2015) 0.79
Nutritional status in relation to lifestyle in patients with compensated viral cirrhosis. World J Gastroenterol (2012) 0.79
Management of patients with difficult autoimmune hepatitis. Therap Adv Gastroenterol (2012) 0.79
Role of serum adiponectin level in the development of liver cirrhosis in patients with hepatitis C virus. Clin Exp Med (2010) 0.79
Mechanisms of intrahepatic triglyceride accumulation. World J Gastroenterol (2016) 0.79
Changes of serum omentin-1 levels and relationship between omentin-1 and insulin resistance in chronic hepatitis C patients. EXCLI J (2013) 0.79
Insulin resistance derived from zinc deficiency in non-diabetic patients with chronic hepatitis C. Exp Ther Med (2010) 0.78
Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C? World J Gastroenterol (2013) 0.78
Apolipoprotein-AII concentrations are associated with liver steatosis in patients with chronic hepatitis C. Dig Dis Sci (2007) 0.78
Association of hepatitis C virus with insulin resistance: evidences from animal studies and clinical studies. Hepat Mon (2012) 0.77
Plasma triglyceride levels may modulate hepatitis C viral replication. Dig Dis Sci (2014) 0.77
Relation of insulin resistance and liver fibrosis progression in patients with chronic hepatitis C virus infection. Int J Health Sci (Qassim) (2009) 0.77
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol (2016) 0.77
Chronic hepatitis c genotype-4 infection: role of insulin resistance in hepatocellular carcinoma. Virol J (2011) 0.77
Assessment of factors associated with pre-diabetes in HCV infection including direct and dynamic measurements of insulin action. J Viral Hepat (2011) 0.77
Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. World J Hepatol (2014) 0.76
The impact of host factors on management of hepatitis C virus. Hepat Mon (2012) 0.76
PI3K/SHIP2/PTEN pathway in cell polarity and hepatitis C virus pathogenesis. World J Hepatol (2017) 0.75
Association of PNPLA3 I148M Variant With Chronic Viral Hepatitis, Autoimmune Liver Diseases and Outcomes of Liver Transplantation. Hepat Mon (2015) 0.75
Statin efficacy in the treatment of hepatitis C genotype I. J Res Med Sci (2014) 0.75
Effect of soy protein supplementation in patients with chronic hepatitis C: a randomized clinical trial. World J Gastroenterol (2012) 0.75
Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus). PLoS One (2017) 0.75
HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients. PLoS One (2012) 0.75
Hepatic lipogranulomas in patients with chronic liver disease: association with hepatitis C and fatty liver disease. World J Gastroenterol (2010) 0.75
Influence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C. Infect Agent Cancer (2016) 0.75
HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients. Gastroenterol Res Pract (2015) 0.75
Prevalence of hepatic steatosis and associated factors in Iranian patients with chronic hepatitis C. Med J Islam Repub Iran (2016) 0.75
Interrelationship between insulin resistance and portal haemodynamic abnormality in cirrhosis. Int J Med Sci (2017) 0.75
Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review. World J Gastroenterol (2017) 0.75
Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study. Int J Gen Med (2013) 0.75
The impact of host metabolic factors on treatment outcome in chronic hepatitis C. Gastroenterol Res Pract (2012) 0.75
Genetic variation in the microsomal triglyceride transfer protein (-493G/T) is associated with hepatic steatosis in patients infected with hepatitis C virus. BMC Infect Dis (2017) 0.75
Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis. Dig Dis Sci (2017) 0.75
Verification of B-lymphocyte activating factor's involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver disease. Diabetol Metab Syndr (2017) 0.75
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (1996) 12.47
Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science (2003) 11.39
Obesity and insulin resistance. J Clin Invest (2000) 10.47
Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology (1994) 9.86
Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care (2000) 9.10
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology (2003) 8.75
Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet (1992) 6.28
Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med (2000) 5.13
Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med (2004) 5.04
Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med (2000) 4.83
Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology (1999) 4.59
Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology (2002) 4.34
Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology (2004) 4.16
Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology (1999) 4.14
Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology (2003) 4.10
Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology (2001) 3.80
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology (2003) 3.23
Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J (2002) 3.06
Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology (2002) 3.02
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol (2000) 2.68
Measurement of liver-iron concentration in needle-biopsy specimens. Lancet (1971) 2.65
High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology (2001) 2.41
Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol (2002) 2.33
Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology (1993) 2.20
Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology (1999) 2.02
Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care (1999) 2.01
Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol (2001) 1.98
The pathology of hepatitis C. Hepatology (1992) 1.92
Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol (2001) 1.89
Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology (2002) 1.88
The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology (1992) 1.85
Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology (2003) 1.70
Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol (2001) 1.68
Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol (1996) 1.46
Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology (1994) 1.34
Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol (2003) 1.13
Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol (2002) 1.13
High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterol Clin Biol (1996) 1.11
Glucose intolerance and insulin resistance in cirrhosis are normalized after liver transplantation. Hepatology (1999) 0.91
Diabetes mellitus and chronic hepatitis C virus infection. Hepatology (1999) 0.83
Assessment of the transferrin index in screening heavy drinkers from a general practice. Alcohol Clin Exp Res (1989) 0.81
Albumin messenger RNA as a marker of circulating hepatocytes in hepatocellular carcinoma. Gastroenterology (1994) 2.62
Retrorectal developmental cysts in adults: clinical and radiologic-histopathologic review, differential diagnosis, and treatment. Radiographics (2001) 2.34
Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med (1994) 2.31
Creatine kinase-BB: a marker of liver sinusoidal damage in ischemia-reperfusion. Hepatology (1993) 2.23
Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology (1998) 2.06
Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology (1999) 2.05
Differential HFE allele expression in hemochromatosis heterozygotes. Gastroenterology (2000) 2.04
Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol (2001) 1.98
A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med (1991) 1.92
Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology (1998) 1.85
Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology (1988) 1.79
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat (2005) 1.64
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology (1997) 1.63
Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Pathol (1999) 1.58
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology (1984) 1.56
MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology (2001) 1.55
Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? J Hepatol (2001) 1.54
Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet (1987) 1.52
Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology (1992) 1.43
Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol (2010) 1.42
Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Liver Transpl Surg (1999) 1.41
Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol (1993) 1.39
Choledocho-ureteral anastomosis in the rat. A new experimental model of long-term, total, internal bile diversion. J Hepatol (1993) 1.39
Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem (1996) 1.38
Solitary fibrous tumor of the adrenal gland. Mod Pathol (1996) 1.38
PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest (2000) 1.32
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat (2007) 1.29
Hepatic stellate cell proliferation is an early platelet-derived growth factor-mediated cellular event in rat cholestatic liver injury. Lab Invest (2001) 1.27
Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol (1994) 1.26
Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. J Viral Hepat (2011) 1.24
Fetal microchimerism in primary biliary cirrhosis. J Hepatol (2000) 1.20
Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease. Inflamm Bowel Dis (2009) 1.13
Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate. Br J Cancer (2008) 1.13
Risk factors for hepatitis C virus infection in hepatitis C virus antibody ELISA-positive blood donors according to RIBA-2 status: a case-control survey. Hepatology (1993) 1.12
Pharmacological effect of somatostatin on bile secretion in man. Digestion (1989) 1.11
The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology (2000) 1.06
Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology (1992) 1.06
Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin Pharmacol Ther (1990) 1.04
Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol (2000) 1.04
Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol (1994) 1.03
Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma. Histopathology (2003) 1.03
Ciliated hepatic foregut cyst with extensive squamous metaplasia: report of a case. Virchows Arch (2006) 1.03
Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. Hepatology (1985) 1.03
Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology (1990) 1.02
Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol (1995) 1.01
Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: relationship with the CD4 cell counts. Eur J Endocrinol (1995) 1.01
Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol (1990) 1.00
Liver adenoma and focal nodular hyperplasia in a man with high endogenous sex steroids. Gastroenterology (1987) 0.99
Serum hyaluronan as a marker of liver fibrosis. J Hepatol (1995) 0.97
Immunohistochemical analysis of adenocarcinoma of the small intestine: a tissue microarray study. J Clin Pathol (2003) 0.97
Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology (1993) 0.96
Adenosarcoma arising in hepatic endometriosis. Eur Radiol (2000) 0.96
Gender and liver: is the liver stiffness weaker in weaker sex? Hepatology (2006) 0.96
Hepatocellular carcinoma and focal hepatic glycogenosis after prolonged azathioprine therapy. Hum Pathol (2000) 0.96
Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol (2001) 0.95
Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology (1999) 0.95
Bile acid transport and regulating functions in the human biliary epithelium. Hepatology (2001) 0.95
[Rectal adenocarcinoma in association with lymphoma ("collision tumor")]. Gastroenterol Clin Biol (1990) 0.95
Absence of anti-LKM-1 antibody in hepatitis C viral infection in the United States of America. J Viral Hepat (1995) 0.94
CT and MR imaging features of pathologically proven atypical giant hemangiomas of the liver. AJR Am J Roentgenol (2002) 0.93
Effect of lysine acetylsalicylate on biliary lipid secretion in dogs. Clin Sci Mol Med (1975) 0.93
Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology (1996) 0.92
Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology (1990) 0.92
Circulating albumin messenger RNA in hepatocellular carcinoma: results of a multicenter prospective study. Hepatology (1997) 0.90
[Celiac disease in adults. (48 cases) I. Anatomo-clinical, biological and radiological study; its course under a non-gluten diet]. Arch Fr Mal App Dig (1975) 0.90
[Tienilic acid-induced hepatitis associated with liver/kidney microsomal antibody (author's transl)]. Nouv Presse Med (1980) 0.89
Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat (2009) 0.89
Expression of blood group antigens including HLA markers in human adult liver. Tissue Antigens (1986) 0.89
Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twenty-seven cases in cirrhotic patients. Hepatology (1990) 0.88
Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology (1993) 0.88
Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. Hepatology (1997) 0.88
Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology (2001) 0.88
Elastography in hepatology. Can J Gastroenterol (2007) 0.87
Littoral-cell angioma as a cause of splenomegaly. N Engl J Med (2001) 0.87
Comparison of a new method for the direct and simultaneous assessment of LDL- and HDL-cholesterol with ultracentrifugation and established methods. Clin Chem (2000) 0.87
Effects of ursodeoxycholic acid and chenodeoxycholic acid on human hepatocytes in primary culture. Hepatology (1995) 0.87
Endothelin-1 secretion by human gallbladder epithelial cells in primary culture. Lab Invest (1993) 0.87
[Peritoneal tuberculosis. Value of laparoscopy]. J Gynecol Obstet Biol Reprod (Paris) (1997) 0.86
Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmacol Exp Ther (1988) 0.86
Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology (1992) 0.86
Bile acids modulate the interferon signalling pathway. Hepatology (1999) 0.85
Metabolism of alpha-ketoisocaproic acid in isolated perfused liver of cirrhotic rats. Am J Physiol (1995) 0.85
Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients. J Viral Hepat (2011) 0.85
Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology (1994) 0.85
Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology (1990) 0.85